February 2026
Psilocybin
What February 2026's 25 new studies found, synthesized from the papers below. All Psilocybin research →
The synthesis
Synthesized from 17 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, then ranked by relevance.
Research on psilocybin in February 2026 shows promising but preliminary therapeutic effects across several conditions, including post-treatment Lyme disease, treatment-resistant depression, and OCD, with improvements often sustained for months. However, evidence is limited by small sample sizes, open-label designs, and a lack of robust placebo controls in many studies, and a microdosing trial for MDD found no difference from placebo. The main caveat is that while acute effects and short-term safety appear favorable, long-term data and large-scale confirmatory trials are still needed.
Confidence in the evidence
Low-Moderate- Multiple small open-label or pilot studies (e.g., n=20, n=30) show positive effects, but lack placebo controls, limiting causal inference.
- One small (n=39) double-blind RCT on microdosing for MDD found no difference from placebo, conflicting with positive open-label findings.
- Naturalistic (n=88) and feasibility (n=20) studies show improvements but are uncontrolled and subject to expectancy effects.
- Systematic review (32 studies) notes small samples and difficulty with placebo blinding as common limitations across the field.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations 2026 | review | Supports | Clinical trials report therapeutic effects of psilocybin for MDD, depressive symptoms in life-threatening illness, and some substance use disorders, but data for OCD and bipolar depression are limited. | |
| Pilot study of psilocybin in patients with post-treatment lyme disease 2026 | open-label pilot | 20 | Supports | Significant improvements in PTLD symptom burden and quality of life from baseline through 6 months, with a 40% decrease in symptom burden at 6 months. |
| Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial 2026 | RCT | 39 | No effect | Microdosing psilocybin (2 mg) did not differ from placebo in reducing depression scores after 4 weeks. |
| Mental health outcomes following a psilocybin session within Oregon’s state-regulated model: A naturalistic study 2026 | naturalistic | 88 | Supports | Significant improvements in depression, anxiety, and well-being at 30 days post-session. |
| Effects of Psilocybin and Select Pharmaceutical Interactions 2026 | review | Unclear | Fluoxetine appears to attenuate psilocybin's effects, and benzodiazepines may be used to manage overwhelming experiences, but interactions are complex. | |
| Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review 2026 | narrative review | Supports | Psilocybin-assisted psychotherapy is a compelling option for psycho-existential distress in palliative settings, warranting further research. | |
| Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis 2026 | qualitative | 7 | Supports | Participants viewed psilocybin as a needed alternative for cancer-related distress, but illegality was a barrier. |
| Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature 2026 | systematic review | 32 | Mixed | Psychedelics enhanced emotional empathy but had mixed effects on memory, attention, and cognitive flexibility, with many studies having small samples. |
| Network pharmacology and molecular simulation reveal the entourage effect mechanisms of psilocybin-producing mushrooms on the brain 2026 | computational | Supports | Computational modeling suggests whole mushroom extracts may have greater efficacy than isolated psilocybin due to multi-target interactions. | |
| Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway 2026 | preclinical | Supports | Psilocybin microdosing rescued object recognition memory deficits via BDNF/TrkB signaling, independent of 5-HT2A or 5-HT1A receptor activation. | |
| Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study 2026 | open-label feasibility | 20 | Supports | Group psilocybin therapy was feasible and showed significant decreases in depression scores with strong effect sizes. |
| Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice 2026 | correction | Supports | The 5-HT1B receptor is implicated in mediating some behavioral and neural effects of psilocybin, including antidepressant-like effects. | |
| Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression 2026 | secondary analysis of RCT | 30 | Supports | Psilocybin-assisted psychotherapy significantly reduced anhedonia at 2 weeks, with improvements sustained at 3 and 6 months. |
| Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD 2026 | exploratory analysis of RCT | 27 | Supports | Greater mystical-type experiences during psilocybin predicted lower OCD severity at 1 and 12 weeks. |
| Activity-Dependent Neural Rewiring by Psilocybin: A Monosynaptic Rabies Virus Tracing Study 2026 | preclinical | Supports | Psilocybin triggers activity-dependent neural rewiring, strengthening sensory-motor pathways and weakening cortical-cortical feedback loops. | |
| Activity-Dependent Neural Rewiring: Mechanisms of Psilocybin-Induced Cortical Network Reorganization 2026 | review | Supports | Psilocybin induces network-specific reorganization that depends on neural activity during administration, suggesting potential for optimized therapy. | |
| Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds. 2026 | position statement | Unclear | Clinical trials face challenges including nonresponse, expectancy effects, functional unblinding, and post-session difficulties. |
Clinical trials report therapeutic effects of psilocybin for MDD, depressive symptoms in life-threatening illness, and some substance use disorders, but data for OCD and bipolar depression are limited.
review
Significant improvements in PTLD symptom burden and quality of life from baseline through 6 months, with a 40% decrease in symptom burden at 6 months.
open-label pilot Sample size: 20
Microdosing psilocybin (2 mg) did not differ from placebo in reducing depression scores after 4 weeks.
RCT Sample size: 39
Significant improvements in depression, anxiety, and well-being at 30 days post-session.
naturalistic Sample size: 88
Fluoxetine appears to attenuate psilocybin's effects, and benzodiazepines may be used to manage overwhelming experiences, but interactions are complex.
review
Psilocybin-assisted psychotherapy is a compelling option for psycho-existential distress in palliative settings, warranting further research.
narrative review
Participants viewed psilocybin as a needed alternative for cancer-related distress, but illegality was a barrier.
qualitative Sample size: 7
Psychedelics enhanced emotional empathy but had mixed effects on memory, attention, and cognitive flexibility, with many studies having small samples.
systematic review Sample size: 32
Computational modeling suggests whole mushroom extracts may have greater efficacy than isolated psilocybin due to multi-target interactions.
computational
Psilocybin microdosing rescued object recognition memory deficits via BDNF/TrkB signaling, independent of 5-HT2A or 5-HT1A receptor activation.
preclinical
Group psilocybin therapy was feasible and showed significant decreases in depression scores with strong effect sizes.
open-label feasibility Sample size: 20
The 5-HT1B receptor is implicated in mediating some behavioral and neural effects of psilocybin, including antidepressant-like effects.
correction
Psilocybin-assisted psychotherapy significantly reduced anhedonia at 2 weeks, with improvements sustained at 3 and 6 months.
secondary analysis of RCT Sample size: 30
Greater mystical-type experiences during psilocybin predicted lower OCD severity at 1 and 12 weeks.
exploratory analysis of RCT Sample size: 27
Psilocybin triggers activity-dependent neural rewiring, strengthening sensory-motor pathways and weakening cortical-cortical feedback loops.
preclinical
Psilocybin induces network-specific reorganization that depends on neural activity during administration, suggesting potential for optimized therapy.
review
Clinical trials face challenges including nonresponse, expectancy effects, functional unblinding, and post-session difficulties.
position statement
Points of agreement
- Psilocybin shows therapeutic potential across multiple conditions including depression, anxiety, and OCD.
- Acute subjective experiences (e.g., mystical-type) may predict clinical outcomes.
- Short-term safety appears favorable under controlled conditions.
- Neural plasticity and network reorganization are key mechanisms.
Conflicts
- Microdosing psilocybin (2 mg) showed no benefit over placebo for MDD in one RCT, while open-label studies with higher doses show positive effects.
- Some studies find psilocybin impairs cognitive functions acutely, while others find enhancements, depending on task and timing.
Gaps
- Long-term safety and efficacy data are lacking.
- Most studies have small sample sizes and lack adequate blinding.
- Research in underrepresented populations (e.g., low-income, diverse ethnic groups) is minimal.
- Mechanisms of action, especially the role of specific receptors and neural circuits, are still being elucidated.
- Durability of effects beyond 6 months is not well studied.